Argos Therapeutics Inc. (NASDAQ:ARGS)’s share price traded up 6.6% during mid-day trading on Friday . The company traded as high as $6.24 and last traded at $6.13, with a volume of 120,453 shares traded. The stock had previously closed at $5.75.

A number of equities analysts have recently issued reports on the company. Roth Capital increased their target price on Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, April 19th. Needham & Company LLC reissued a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, April 23rd. Stifel Nicolaus cut their target price on Argos Therapeutics from $16.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, March 30th. Zacks Investment Research raised Argos Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research note on Friday, April 1st. Finally, FBR & Co reissued a “buy” rating on shares of Argos Therapeutics in a research note on Tuesday, June 14th. Eight research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $11.84.

The stock’s market cap is $161.56 million. The company has a 50 day moving average of $6.10 and a 200 day moving average of $5.26.

Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by $0.01. Equities analysts expect that Argos Therapeutics Inc. will post ($1.74) EPS for the current year.

Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.